13 completed, 1 terminated, 1 withdrawn. 7 Phase 1, 6 Phase 2, 3 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Withdrawn 1 |
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 3 | Completed 3 |
| Early Phase 1 | 1 | Completed 1 |
Follow EA Pharma Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g), Elobixibat 10mg + cholestyramine powder placebo, Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g) - Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | Phase 2 | Completed | Yokohama City University | 102 | 2020-01-29 | 2021-11-16 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants EA1080, EA1080-matching placebo - Healthy Volunteers | Phase 1 | Completed | EA Pharma Co., Ltd. | 184 | 2020-01-09 | 2023-12-26 |
| A Study of E6011 in Participants With Active Crohn's Disease E6011, Placebo - Crohn's Disease | Phase 2 | Completed | EA Pharma Co., Ltd. | 25 | 2019-04-25 | 2025-04-02 |
| A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants E3112, Placebo - Healthy Male Participants | Phase 1 | Completed | EA Pharma Co., Ltd. | 24 | 2019-04-22 | 2021-03-15 |
| A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis AJM300, Placebo - Colitis, Ulcerative | Phase 3 | Completed | EA Pharma Co., Ltd. | 198 | 2018-06-06 | 2023-07-21 |
| A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants [14C]-E6007 - Healthy Male Participants | Phase 1 | Completed | EA Pharma Co., Ltd. | 6 | 2018-04-17 | 2018-08-29 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants E6130, Placebo - Healthy Participants | Phase 1 | Withdrawn | EA Pharma Co., Ltd. | 2017-12-21 | 2018-07-31 | |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State AJM347, Placebo - Healthy Participants | Phase 1 | Completed | EA Pharma Co., Ltd. | 200 | 2017-07-25 | 2018-08-29 |
| Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid E6011, Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | EA Pharma Co., Ltd. | 29 | 2017-05-29 | 2019-01-04 |
| A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects Placebo, E3112 - Healthy Male Volunteers | Early Phase 1 | Completed | EA Pharma Co., Ltd. | 29 | 2017-01-25 | 2018-11-14 |
| Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis E6007, Placebo - Moderate Active Ulcerative Colitis | Phase 2 | Completed | EA Pharma Co., Ltd. | 147 | 2016-11-28 | 2019-10-04 |
| General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation AJG555 - Chronic Constipation | Phase 3 | Completed | EA Pharma Co., Ltd. | 39 | 2016-11-15 | 2017-10-24 |
| A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects E6130, Placebo - Japanese Healthy Adult Male Participants | Phase 1 | Completed | EA Pharma Co., Ltd. | 56 | 2016-09-26 | 2018-09-06 |
| A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease E6011 2 mg/kg, E6011 5 mg/kg, E6011 10 mg/kg - Crohn's Disease | Phase 1 / Phase 2 | Completed | EA Pharma Co., Ltd. | 28 | 2014-04-05 | 2023-01-30 |
| A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets NE-58095 IR, NE-58095 IR Placebo, NE-58095 DR - Involutional Osteoporosis | Phase 2 / Phase 3 | Completed | Takeda | 871 | 2014-02-01 | 2017-02-23 |
Crohn Disease (2) · Colitis (1) · Colitis, Ulcerative (1) · Constipation (1) · Gastroenteritis (1) · Inflammatory Bowel Diseases (1) · Liver Cirrhosis, Biliary (1) · Non-alcoholic Fatty Liver Disease (1) · Osteoporosis (1)
quetmolimab (3) · AJM300 (1) · Cholestyramine Resin (1) · elobixibat (1)
Japan (11) · United Kingdom (3) · Czechia (1) · Hungary (1) · Poland (1) · Russia (1)
PMID 29805116, PMID 32907904, PMID 33599356, PMID 35366419
2017 (2), 2018 (1), 2019 (1)